Respiratory Testing Enters a Period of Recalibration
As pandemic-era practices give way to more tailored strategies, laboratories are reconsidering how much respiratory testing is appropriate for different patients and clinical situations.
As pandemic-era practices give way to more tailored strategies, laboratories are reconsidering how much respiratory testing is appropriate for different patients and clinical situations.
Alveo Technologies and UTMB have partnered to develop point-of-care diagnostics for Lassa fever, deploying molecular sensing platforms at clinical sites in Nigeria and Sierra Leone to support real-time pathogen detection.
New analysis suggests that higher-sensitivity testing could lower annual spending by more than $3 billion by reducing misdiagnosis.
WHO has added the first molecular diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing, aiming to support rapid infection confirmation and surveillance during the ongoing outbreak in Central Africa.
The system simultaneously detects RSV, influenza A and B, and SARS-CoV-2 from a nasal swab in under 10 minutes.
The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.
A randomized trial found Cepheid’s Xpert Xpress MVP test improved appropriate treatment rates for vaginitis within 24 hours compared to standard diagnostic methods.